Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 1
Ce profil est validé par 1 label.

Company

Inflection Biosciences Ltd

Inflection Biosciences Ltd_logo
18
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

Inflection Biosciences pipeline includes first-in-class IBL-202, a dual PIM and PI3K inhibitor in development for B-cell malignancies, the IBL-100s (PIM kinase inhibitors) and AUM302, partnered with AUM Biosciences.

Dublin, Dublin, Ireland

Send a message

  • 2

    employees

  • €0

    turnover

Anglais

Inflection Biosciences Ltd

Anglais

Inflection Biosciences Ltd, based in Dublin, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). IBL-202 is a first-in-class PIM/PI3K inhibitor with pre-clincial data supporting its potential in B-cell malignancies, a series of cancers diagnosed in 700,000 globally each year with 250,000 deaths. The IBL-100 series comprises selective...

See more

Inflection Biosciences Ltd, based in Dublin, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). IBL-202 is a first-in-class PIM/PI3K inhibitor with pre-clincial data supporting its potential in B-cell malignancies, a series of cancers diagnosed in 700,000 globally each year with 250,000 deaths. The IBL-100 series comprises selective pan-PIM kinase inhibitors with pre-clinical proof of concept in AML and lung cancer. The copmany's partnered pipeline comprises AUM302 is a first-in-class, orally available PIM/PI3K/mTOR inhibitor, partnered with AUM Biosciences. Pre-clincal proof of conept in breast cancer, lung cancer, AML and neuroblastoma has been generated, with results published in peer review EMBO Molecular Medicine in 2019.  The quality of company's research has been recognised in its receipt of funding from the European Union's Horizon 2020 in 2019. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com

  • 1

    Followers

  • 1

    Like

Our latest news

Certifications

Seal of Excellence
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not received funding due to budget limits. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
1275 Entities

Communities

InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
1138 Members
Access2EIC – Seal of Excellence
The Access2EIC -Seal of Excellence community aims at gathering high potential European companies that received from the European Commission a “Seal of Excellence” certificate and European equity investors. https://access2eic.eu/
1788 Members

Our history

Start in 31/12/2012

  • 31/12/2012

    Inflection Biosciences Ltd incorporated in Dublin, Ireland

  • 28/05/2013

    Cancer pipeline secure via licensing agreement with Spanish National Cancer Research Centre (CNIO)

  • 1/10/2014

    Awarded Start Up of the year at Pharma Awards

  • 28/5/2018

    IBL-202 peer review publication in British Journal of Hematology

  • 1/7/2019

    AUM302 out-licensing to AUM Biosciences, Singapore

to be continued ...